John Houston
Chief Executive Officer bij ARVINAS, INC.
Vermogen: 43 M $ op 31-03-2024
Profiel
John G. Houston bekleedt de functie van President, Chief Executive Officer & Director bij Arvinas, Inc. en President, Chief Executive Officer & Director bij Arvinas Operations, Inc. (een dochteronderneming van Arvinas, Inc.). Hij zit ook in de raad van bestuur van NextCure, Inc., Cybrexa, Inc. en Oerth Bio LLC. John G. Houston bekleedde voorheen de functie van Senior Vice President-Specialty Discovery bij Bristol Myers Squibb Co. en Head-Lead Discovery Unit bij GlaxoSmithKline Research & Development Ltd. Hij behaalde een doctoraat aan de Universiteit van Glasgow en een doctoraat aan de Heriot-Watt Universiteit.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ARVINAS, INC.
1.52% | 23-02-2024 | 1 036 681 ( 1.52% ) | 43 M $ | 31-03-2024 |
NEXTCURE, INC.
-.--% | 22-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van John Houston
Bedrijven | Functie | Begin |
---|---|---|
ARVINAS, INC. | Chief Executive Officer | 01-09-2017 |
NEXTCURE, INC. | Director/Board Member | 10-09-2020 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Chief Executive Officer | 21-09-2017 |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director/Board Member | 03-09-2019 |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky. | Director/Board Member | - |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT. | Director/Board Member | - |
Bioct Innovation Commons | Director/Board Member | - |
Eerdere bekende functies van John Houston
Bedrijven | Functie | Einde |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-08-2016 |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The private company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc. | Corporate Officer/Principal | - |
Opleiding van John Houston
University of Glasgow | Doctorate Degree |
Heriot-Watt University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ARVINAS, INC. | Health Technology |
NEXTCURE, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT. | Commercial Services |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The private company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc. | Commercial Services |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky. | Health Technology |
Bioct Innovation Commons |